From the Director, Prof Chris Rowe
Welcome to the April edition of the ADNeT Newsletter.
Following from the FDA approval of Lecanemab in January, exciting new results have been released from Phase 3 trials of Eli Lilly’s new Alzheimer’s drug Donanemab. After decades of Alzheimer’s research it seems we are entering a new era in successful dementia research and treatments.
Please enjoy our ‘Spotlight On” interview segment with Professor Sharon Naismith, whose research work on music as an intervention for cognitive decline and novel blood-tests for diagnosing dementia, has been making the news.
We look forward to seeing you at the upcoming Australian Dementia Research Forum. Please check out the event website for more information and secure your tickets before registrations close on May 19th.
I hope you enjoy the other ADNeT news and updates. You can read the newsletter by accessing the News section of the ADNeT website.